Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.
about
Inhaled protein/peptide-based therapies for respiratory diseaseSystematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future DirectionsInhaled nano- and microparticles for drug deliveryPulmonary-intestinal cross-talk in mucosal inflammatory diseaseFundamentals of aerosol therapy in critical careParticle transport and deposition: basic physics of particle kineticsPulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countriesTolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis PatientsHygroscopic Properties and Respiratory System Deposition Behavior of Particulate Matter Emitted By Mining and Smelting OperationsDevelopment of an ex vivo human-porcine respiratory model for preclinical studies.The role of disposable inhalers in pulmonary drug delivery.Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.Clinical experimentation with aerosol antibiotics: current and future methods of administration.Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalersSpectroscopic characterisation and manipulation of arrays of sub-picolitre aerosol droplets.Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agentOrgan-on-a-chip platforms for studying drug delivery systems.Small airways dysfunction in asthma: evaluation and management to improve asthma control.Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancerBiologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy.Aerosol deposition characteristics in distal acinar airways under cyclic breathing conditions.Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosisDelivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.Convective flow dominates aerosol delivery to the lung segmentsA safety evaluation of DAS181, a sialidase fusion protein, in rodents.V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical resultsBiological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells.Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.Targeted delivery of liquid microvolumes into the lung.Fluorescence lifetime imaging of optically levitated aerosol: a technique to quantitatively map the viscosity of suspended aerosol particles.Feasibility of tissue plasminogen activator formulated for pulmonary delivery.Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors.Surfactant Driven Post-Deposition Spreading of Aerosols on Complex Aqueous Subphases. 2: Low Deposition Flux Representative of Aerosol Delivery to Small Airways.Aerosol delivery devices and obstructive airway disease.Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases.
P2860
Q26751439-80A9BA8C-D349-499F-94D1-563440BA3FECQ26769743-9F5D1A3A-AADB-4C99-8350-746BA9570B66Q26771328-545B2EA7-3136-4393-98A9-0B7F367B36BAQ27693862-546BF778-2790-409C-8887-6DAAC01915F3Q28068836-9F07A099-4FFE-4A24-AA5A-1AFE309C7563Q28391883-BD13AAFD-C608-4948-A195-1E1959DC040FQ28537941-CF336101-7D15-4EBB-971E-EDF38A7EE42FQ28550641-ED585E1F-654D-469E-A78C-EDB1A2045FC1Q28822497-5B327105-890F-4A26-844E-4A5431218BD3Q29247899-8F559F6D-DB6B-47F9-9344-E70C66252B4CQ30368417-B7CC005E-B6A9-4F25-9EAA-A48E7E7CD49CQ30401897-423714F4-EDBA-4F9A-B93D-25C3F8FBDE5BQ30448377-BA1F334B-7D10-44D9-9898-C3B2194A88FFQ30498062-A6D8BBCF-A079-4383-A23C-D1D5BA2EBE3FQ33405259-C0291419-95A4-41B0-A43C-12DD3B74F418Q33688875-0D1DEB6C-3BC0-4EDD-A8A4-2804BFFCB25CQ33811796-B468593F-AF60-432E-BAAF-38A761D3556EQ34079592-54CF605E-AD3D-4C23-9C0F-78EF611E90F7Q34167882-8986AC28-6A8B-4CB2-86DD-A51FBD6927D4Q34300257-0B62C16F-E3E2-498A-9F4B-8AB4C0B02ADCQ34577401-58640F3A-02F8-4551-8D9A-F3EFF87A1E1FQ34577430-95BBB57F-D8C1-4049-A22C-36085A7C35C5Q34594731-92EE94A8-14CD-4DB1-B71C-25873341C094Q34747045-34D36BE1-E67D-4242-8F69-D59CA23F88A6Q34994586-45C19DB6-2203-429F-950E-339BD55566F5Q35034689-F029F8B0-3871-4205-97DE-87D54C4678F6Q35096988-000E1DCD-3AAF-421D-ADBD-490F86996C81Q35108771-CECC98A2-C2F5-4F7D-816A-6D38F62DE6D9Q35161415-27A7224D-82A5-4D42-AEF5-C07489E24851Q35710238-931E4859-01B1-440F-A7A1-4D8A43113C77Q35735440-56387B0B-D914-4922-8953-9DB9AF663824Q35768436-22DE0297-FF5F-4159-B900-6A5B07F599F4Q36078988-CA8838D8-851E-44CB-B787-15CE5A1F5AD0Q36080558-CBF849C3-9B2F-4D19-9A71-C001D72CC69DQ36088869-FC25E1E0-EED6-43DC-B09B-9334136F7D70Q36132725-BF277867-00CF-494B-B731-4FF224C74FF3Q36148239-760278B5-2B79-45CD-B008-3510CE7D83E2Q36315050-38E8E867-9DFB-493B-A100-71385C847F04Q36321710-2D520213-D49E-4DF2-B18C-EE4E8EFFAD7EQ36360151-FDC9723F-7978-4B8E-8BD6-B4BA0839E65C
P2860
Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@ast
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@en
type
label
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@ast
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@en
prefLabel
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@ast
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@en
P2860
P1476
Pulmonary drug delivery. Part ...... ss of aerosolized medications.
@en
P2093
M B Dolovich
N R Labiris
P2860
P304
P356
10.1046/J.1365-2125.2003.01892.X
P407
P577
2003-12-01T00:00:00Z